Kintara Therapeutics (KTRA) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kintara Therapeutics, in collaboration with TuHura Biosciences, has reported promising outcomes from their Phase 1b trial, showcasing that their novel cancer vaccine, IFx-2.0, is both safe and effective in treating advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma resistant to standard checkpoint inhibitor therapies. A noteworthy 80% response rate was observed in ICI naïve patients with advanced MCC, demonstrating significant potential for IFx-2.0 to overcome immunotherapy resistance. These results were presented at the prestigious ASCO Annual Meeting, highlighting a major step forward in cancer immunotherapy.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.